【摘要】 目的 观察阿那曲唑(瑞宁得)治疗晚期乳腺癌的疗效及不良反应。方法 39例晚期乳腺癌患者给予瑞宁得1mg口服，每日1次。结果 39例患者中，可评价疗效39例，可评价不良反应39例。完全缓解(CR)0例；部分缓解(PR)5例，占12.8%；稳定(SD)26例，占66.7%，其中病情稳定≥6个月8例，占20.5%；临床获益患者(CR+PR+SD≥6个月)13例，占33.3%；病情进展(PD)8例，占20.5%。一线治疗7例，PR 2例，有效率为28.6%，临床获益率57.1%。二线治疗15例，PR 2例，有效率为13.3%，临床获益率33.3%。三线及以上治疗17例，PR 1例，有效率5.9%，临床获益率29.4%。软组织、骨和内脏转移有效率依次为17.6%、8.3%和9.1%。结论 瑞宁得治疗晚期乳腺癌有一定疗效，药物不良反应轻，患者易于耐受。

    【关键词】 乳腺肿瘤；治疗；瑞宁得

    Arimidex in the treatment of advanced breast cancer

    ZHUANG Yong-zhi,ZHAO Jiu-jun,HE Zhong-jie.Center for Tumor Therapy,Daqing Oilfield General Hospital,Daqing 163001,China

    【Abstract】 Objective To evaluate the efficacy and adverse effects of Arimidex for postmenopausal patients with advanced breast cancer.Methods 39 patients with advanced breast cancer received 1mg/d arimidex as a single agent.Results All patients were evaluable for adverse effects.Among these 39 patients who were evaluable for efficacy,there was no complete response,partial response of 5(12.8%),stable disease of 26(66.7%),progressive disease of 8(20.5%),and clinical benefit (CR+PR+SD≥6months) 20(33.3%).The rate and clinical benefit was 28.6% and 57.1% in first-line treatment,13.3% and 33.3% in second-line treatment,5.9% and 29.4% in more than second-line treatment.The response rate of soft tissue,bone and visceral metastasis was 17.6%、8.3% and 9.1%,respectively.Conclusion Arimidex is a well tolerated agent with reasonable efficacy but low toxicity for postmenopausal patients with advanced breast cancer. ......